Magazine Article | March 1, 2022

Post-COVID Supply Chain Opportunities And Strategies For Biopharmas And CDMOs

Source: Life Science Leader

By Derron Stark and Jay Welsh

The COVID-19 pandemic exposed the dependence on global supply chains, as well as the limited domestic manufacturing capacity in the U.S. for critical medicines and medical devices. Recurring drug and medical device shortages and quality issues related to offshoring also have encouraged U.S. commercial customers to purchase from domestic manufacturers. The government policy response has been an intense focus on building up domestic manufacturing capabilities.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: